3-(2,3,4,9-tetrahydro-1H-β-carbolin-1-yl)-phenol | 6649-84-9

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: 3-(2,3,4,9-tetrahydro-1H-β-carbolin-1-yl)-phenol
• 英文别名: 1-<3-Hydroxy-phenyl>-1,2,3,4-tetrahydro-β-carbolin；3-(2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenol
• CAS: 6649-84-9
• 化学式: C₁₇H₁₆N₂O
• 分子量: 264.327
• InChiKey: PBHDVNKOSVXBHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  48
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Boc-beta-丙氨酸 、 3-(2,3,4,9-tetrahydro-1H-β-carbolin-1-yl)-phenol 在 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 生成
  参考文献：
  名称：

  The discovery of tetrahydro-β-carbolines as inhibitors of the kinesin Eg5

  摘要：

  A series of tetrahydro-beta-carbolines were identified by HTS as inhibitors of the kinesin Eg5. Molecular modeling and medicinal chemistry techniques were employed to explore the SAR for this series with a focus of removing potential metabolic liabilities and improving cellular potency. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.012
• 作为产物：
  描述：

  3-(4,9-dihydro-3H-pyrido[3,4-b]indol-1-yl)phenol 在 sodium tetrahydroborate 作用下， 生成 3-(2,3,4,9-tetrahydro-1H-β-carbolin-1-yl)-phenol
  参考文献：
  名称：

  M4 agonists/5HT7 antagonists with potential as antischizophrenic drugs: Serominic compounds

  摘要：

  Chronic low-dose treatment of rats with the psychomimetic drug, phencyclidine, induces regionally specific metabolic and neurochemical changes in the CNS that mirror those observed in the brains of schizophrenic patients. Recent evidence suggests that drugs targeting serotoninergic and muscarinic receptors, and in particular 5-HT7 antagonists and M-4 agonists, exert beneficial effects in this model of schizophrenia. Compounds that display this combined pattern of activity we refer to as serominic compounds. Based upon leads from natural product screening, we have designed and synthesised such serominic compounds, which are principally arylamidine derivatives of tetrahydroisoquinolines, and shown that they have the required serominic profile in ligand binding assays and show potential antipsychotic activity in functional assays. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.093

文献信息

• Tetrahydrocarboline compounds as anticancer agents
  申请人：Wang Weibo

  公开号：US20050215580A1

  公开（公告）日：2005-09-29

  Tetrahydrocarboline compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the tetrahydrocarboline compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the tetrahydrocarboline compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.

  四氢吲哚烷类化合物，药用可接受盐和前药；包括药用可接受载体和一种或多种四氢吲哚烷类化合物的组合物，可以单独使用或与至少一种其他治疗剂联合使用。使用四氢吲哚烷类化合物的方法，可以单独使用或与至少一种其他治疗剂联合使用，用于预防或治疗增殖性疾病。
• TETRAHYDROCARBOLINE COMPOUNDS AS ANTICANCER AGENTS
  申请人：CHIRON CORPORATION

  公开号：EP1706404A2

  公开（公告）日：2006-10-04
• USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING
  申请人：Alevere Medical Corporation

  公开号：EP2968272B1

  公开（公告）日：2021-06-16
• US7855295B2
  申请人：——

  公开号：US7855295B2

  公开（公告）日：2010-12-21
• [EN] TETRAHYDROCARBOLINE COMPOUNDS AS ANTICANCER AGENTS<br/>[FR] COMPOSES DE TETRAHYDROCARBOLINE COMME AGENTS ANTICANCEREUX
  申请人：CHIRON CORP

  公开号：WO2005070930A2

  公开（公告）日：2005-08-04

  Tetrahydrocarboline compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the tetrahydrocarboline compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the tetrahydrocarboline compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.